| 1 |
34936696 | Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. | 2022 Mar 31 |
1 |
| 2 |
33534410 | The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma. | 2021 Mar 1 |
2 |
| 3 |
33563611 | The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. | 2021 Mar |
3 |
| 4 |
33623139 | IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. | 2021 May |
1 |
| 5 |
34117218 | IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform. | 2021 Jun 11 |
2 |
| 6 |
34168051 | Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma. | 2021 Oct 1 |
2 |
| 7 |
34588172 | Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. | 2021 Dec |
1 |
| 8 |
34680233 | Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. | 2021 Oct 11 |
1 |
| 9 |
31358854 | Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. | 2020 Jan |
1 |
| 10 |
32251398 | Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. | 2020 May |
1 |
| 11 |
32414180 | Molecular Mechanisms of the Teratogenic Effects of Thalidomide. | 2020 May 13 |
1 |
| 12 |
32591583 | Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide. | 2020 Jun 26 |
3 |
| 13 |
32984863 | Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies. | 2020 |
6 |
| 14 |
33284947 | Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. | 2020 Dec 8 |
1 |
| 15 |
33357426 | Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4. | 2020 Dec 22 |
1 |
| 16 |
33392195 | Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. | 2020 |
2 |
| 17 |
29788898 | Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. | 2019 |
3 |
| 18 |
30026574 | A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. | 2019 Jan |
1 |
| 19 |
30760870 | RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. | 2019 Aug |
2 |
| 20 |
31151137 | Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation. | 2019 Sep |
2 |
| 21 |
31157769 | Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. | 2019 May 15 |
1 |
| 22 |
29363546 | Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. | 2018 Apr 1 |
1 |
| 23 |
29588478 | Ikaros family zinc finger 1 regulates dendritic cell development and function in humans. | 2018 Mar 27 |
2 |
| 24 |
30111438 | [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review]. | 2018 Aug |
1 |
| 25 |
30118587 | Homo-PROTACs for the Chemical Knockdown of Cereblon. | 2018 Sep 21 |
2 |
| 26 |
30234487 | UBE2G1 governs the destruction of cereblon neomorphic substrates. | 2018 Sep 20 |
1 |
| 27 |
30385546 | Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. | 2018 Nov 2 |
1 |
| 28 |
28017969 | IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). | 2017 Jun |
3 |
| 29 |
28052520 | IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma. | 2017 Mar |
1 |
| 30 |
28087699 | Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase. | 2017 Mar 3 |
1 |
| 31 |
28643330 | MUC1-C is a target in lenalidomide resistant multiple myeloma. | 2017 Sep |
4 |
| 32 |
28751557 | The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. | 2017 Oct |
1 |
| 33 |
28893618 | Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB. | 2017 Dec |
3 |
| 34 |
28927072 | Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. | 2017 Sep |
5 |
| 35 |
29290933 | Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma. | 2017 Dec 5 |
1 |
| 36 |
27881177 | High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide. | 2016 Nov 21 |
2 |
| 37 |
26430725 | Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. | 2015 Oct 2 |
4 |
| 38 |
26438514 | The novel mechanism of lenalidomide activity. | 2015 Nov 19 |
1 |
| 39 |
24292623 | The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. | 2014 Jan 17 |
4 |
| 40 |
24292625 | Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. | 2014 Jan 17 |
3 |
| 41 |
24328678 | Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). | 2014 Mar |
2 |
| 42 |
24840055 | New mechanism of lenalidomide activity. | 2014 Aug |
2 |
| 43 |
25610725 | Lenalidomide induces degradation of IKZF1 and IKZF3. | 2014 |
1 |